Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer plans to buy Arena Pharmaceuticals for $6.7 billion

By Brian Buntz | December 13, 2021

Pfizer/ArenaPfizer (NYSE:PFE) plans to spend almost $7 billion to acquire Arena Pharmaceuticals (NSDQ:ARNA). The purchase would bolster its pipeline of immuno-inflammatory drugs. 

ARNA shares surged 80% to $90.08 after the announcement. PFE shares ticked up to $55.20 to 4.57%. 

The transaction was valued at $100 per Arena share in cash. 

The proposal has won the unanimous approval of the boards of directors at both firms. 

Arena’s lead candidate etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, offers promise for several immuno-inflammatory diseases, including Crohn’s disease, atopic dermatitis and ulcerative colitis. Arena also has ongoing Phase 2 trials involving etrasimod in eosinophilic esophagitis and alopecia areata.

Earlier this year, Bristol Myers Squibb won the first gastrointestinal indication of an S1P receptor modulator. Known as ozanimod, the drug was branded as Zeopsia. 

Etrasimod has been the subject of 27 clinical studies to date. 

Other drug candidates in Arena’s pipeline include temanogrel and APD418. Temanogrel is a potential for microvascular obstruction and Raynaud’s phenomenon secondary to systemic sclerosis. APD418 is now in a Phase 2 study for acute heart failure.

Arena is also developing a cannabinoid type-2 receptor known as olorinab for the potential treatment of chronic pain, including visceral pain stemming from gastrointestinal disorders. 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE